CoChat
Sign Up
Cited by 138Parkinson's Disease Mechanisms and TreatmentsGastrointestinal motility and disordersDeep Brain Stimulation and Movement Disorders

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Nonmotor gastrointestinal disorders in older patients with Parkinson’s disease: is there hope?

Open access
Georgescu, Doina, Ancusa, Oana, Georgescu, Liviu, Ionita, Ioana, Reisz, Daniela·2016·Clinical Interventions in Aging
DOI 10.2147/cia.s106284PMC PMC5113937
Open this paper in CoChat — free accountOpen PDF

Abstract

Abstract: Despite the fact that nonmotor symptoms (NMS) like gastrointestinal (GI) complaints are frequently reported in Parkinson’s disease (PD), no therapeutic guidelines are available. This study aimed to manage some lower GI-NMS in a group of patients with PD. A total of 40 patients (17 males, 23 females; mean age 76.05±2.09 years) were randomly selected for this study. Patients were confirmed to have PD (modified Hoehn–Yars scale: 2.075±0.4) who had undergone levodopa or dopamine agonist treatment. In the non-motor symptoms questionnaire (NMS-Quest), regarding GI complaints, the following were recorded: abdominal pain, bloating, and constipation of mild-to-moderate severity. Laboratory studies, abdominal ultrasound, and upper and lower digestive endoscopies were performed to rule out organic issues. All patients increased their water intake to 2 L/d and alimentary fiber to 20–25 g/d. Twenty patients received trimebutine 200 mg three times daily half an hour before meals. The other 20 patients received probiotics (60 mg per-tablet of two lactic bacteria: Lactobacillus acidophilus and Bifidobacterium infantis ), 2×/d, 1 hour after meals for 3 months along with the reassessment of GI complaints. Our results demonstrated that there were significant statistical differences in all assessed symptoms in the first group: 1.55±0.51 vs 0.6±0.5 ( P <0.0001) for abdominal pain; 1.6±0.5 vs 0.45±0.51 ( P <0.0001) for bloating; and 1.5±0.51 vs 0.85±0.67 ( P =0.0014) for constipation with incomplete defecation. The second group displayed statistical differences only for abdominal pain 1.45±0.51 vs 1.05±0.69 ( P =0.00432) and bloating 1.4±0.5 vs 0.3±0.47 ( P <0.0001). For constipation with incomplete defecation, there was a slight improvement. Thus, there was no significant statistical difference: 1.35±0.49 vs 1.15±0.49 ( P =0.2040). In conclusion, lower GI-NMS are frequently present, isolated or associated with other autonomic issues, even before the diagnosis of PD. Treatment with probiotics could improve abdominal pain and bloating as much as with trimebutine, but less for constipation with incomplete evacuation, where trimebutine showed better results. Keywords: PD, lower GI-NMS, probiotics, prokinetics, trimebutine

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/cia.s106284

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Presence of GI symptoms in first group: prior to and after the PD diagnosis. Note: First group consisted of 20 PD patients with GI-NMS that received Trimebutine 200 mg three times per day. Abbreviations: GI, gastrointestinal; PD, Parkinson’s disease; NMS, nonmotor symptoms.
Figure 1 Presence of GI symptoms in first group: prior to and after the PD diagnosis. Note: First group consisted of 20 PD patients with GI-NMS that received Trimebutine 200 mg three times per day. Abbreviations: GI, gastrointestinal; PD, Parkinson’s disease; NMS, nonmotor symptoms.CC BY-NC · PubMed Central
Figure 2 Presence of GI symptoms in second group: prior to and after the PD diagnosis. Note: Second group consisted of 20 PD patients with GI-NMS, treated with probiotics. Abbreviations: GI, gastrointestinal; PD, Parkinson’s disease; NMS, nonmotor symptoms.
Figure 2 Presence of GI symptoms in second group: prior to and after the PD diagnosis. Note: Second group consisted of 20 PD patients with GI-NMS, treated with probiotics. Abbreviations: GI, gastrointestinal; PD, Parkinson’s disease; NMS, nonmotor symptoms.CC BY-NC · PubMed Central
Figure 3 Other NMS associated with GI symptoms. Abbreviations: GI, gastrointestinal; NMS, nonmotor symptoms.
Figure 3 Other NMS associated with GI symptoms. Abbreviations: GI, gastrointestinal; NMS, nonmotor symptoms.CC BY-NC · PubMed Central
Figure 4 Multiple different autonomic NMS in the first group population. Note: First group consisted of 20 PD patients with GI-NMS that received Trimebutine 200 mg three times per day. Abbreviations: GI, gastrointestinal; NMS, nonmotor symptoms; PD, Parkinson’s disease.
Figure 4 Multiple different autonomic NMS in the first group population. Note: First group consisted of 20 PD patients with GI-NMS that received Trimebutine 200 mg three times per day. Abbreviations: GI, gastrointestinal; NMS, nonmotor symptoms; PD, Parkinson’s disease.CC BY-NC · PubMed Central
Figure 5 Multiple different autonomic NMS in the second group population. Note: Second group consisted of 20 PD patients with GI-NMS, treated with probiotics. Abbreviations: GI, gastrointestinal; NMS, nonmotor symptoms; PD, Parkinson’s disease.
Figure 5 Multiple different autonomic NMS in the second group population. Note: Second group consisted of 20 PD patients with GI-NMS, treated with probiotics. Abbreviations: GI, gastrointestinal; NMS, nonmotor symptoms; PD, Parkinson’s disease.CC BY-NC · PubMed Central
Figure 6 The outcome in the first group. Note: First group consisted of 20 PD patients with GI-NMS that received Trimebutine 200 mg three times per day. For each patient there are two columns: the first column (left side) represents the symptoms before treatment; the second column (right side) represents the symptoms after treatment. Abbreviations: PD, Parkinson’s disease; GI-NMS, gastrointestinal nonmotor symptoms.
Figure 6 The outcome in the first group. Note: First group consisted of 20 PD patients with GI-NMS that received Trimebutine 200 mg three times per day. For each patient there are two columns: the first column (left side) represents the symptoms before treatment; the second column (right side) represents the symptoms after treatment. Abbreviations: PD, Parkinson’s disease; GI-NMS, gastrointestinal nonmotor symptoms.CC BY-NC · PubMed Central
Figure 7 The outcome in the second group. Note: Second group consisted of 20 PD patients with GI-NMS, treated with probiotics. For each patient there are two columns: the first column (left side) represents the symptoms before treatment; the second column (right side) represents the symptoms after treatment. Abbreviations: PD, Parkinson’s disease; GI-NMS, gastrointestinal nonmotor symptoms.
Figure 7 The outcome in the second group. Note: Second group consisted of 20 PD patients with GI-NMS, treated with probiotics. For each patient there are two columns: the first column (left side) represents the symptoms before treatment; the second column (right side) represents the symptoms after treatment. Abbreviations: PD, Parkinson’s disease; GI-NMS, gastrointestinal nonmotor symptoms.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Georgescu, D., Ancusa, O., Georgescu, L., Ionita, I., & Reisz, D.
Affiliations
Victor Babeș University of Medicine and Pharmacy Timișoara (RO)
Corresponding author
Ancusa, Oana
ORCID
Venue
Clinical Interventions in Aging
Publisher
Informa UK Limited
Published
2016-11
Volume
Volume 11
Pages
1601-1608
ISSN
  • 1176-9092 (ISSN-L)
  • 1178-1998
DOI
10.2147/cia.s106284
PMC
PMC5113937
OpenAlex
W2550869378
Cited by
138
References
29
Citations by year
2026: 5 · 2025: 18 · 2024: 29 · 2023: 21 · 2022: 34 · 2021: 20 · 2020: 5 · 2019: 4 · 2018: 1 · 2017: 1
FWCI
1.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Interventions in Aging (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
Parkinson's disease, non-motor symptoms, gastrointestinal symptoms, constipation, abdominal pain, bloating, trimebutine, probiotics, Lactobacillus acidophilus, Bifidobacterium infantis, dietary fiber, older adults, levodopa, dopamine agonists, symptom management, quality of life, activities of daily living
MeSH terms
Age Factors, Aged, Bifidobacterium, Female, Gastrointestinal Agents, Gastrointestinal Diseases, Humans, Lactobacillus acidophilus, Male, Parkinson Disease, Trimebutine, Probiotics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review